Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,220 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictors of virologic outcome among people living with HIV who continue a protease inhibitor-based antiretroviral regimen following virologic failure with no or limited resistance.
Salata RA, Grinsztejn B, Ritz J, Collier AC, Hogg E, Gross R, Godfrey C, Kumarasamy N, Kanyama C, Mellors JW, Wallis CL, Hughes MD; ACTG A5288 Study Team. Salata RA, et al. Among authors: gross r. AIDS Res Ther. 2023 Jan 5;20(1):3. doi: 10.1186/s12981-022-00494-9. AIDS Res Ther. 2023. PMID: 36604746 Free PMC article.
Adherence to HIV drug therapy.
Gross R. Gross R. LDI Issue Brief. 2002 Nov;8(3):1-4. LDI Issue Brief. 2002. PMID: 12530426
Randomized, controlled trial of therapy interruption in chronic HIV-1 infection.
Papasavvas E, Kostman JR, Mounzer K, Grant RM, Gross R, Gallo C, Azzoni L, Foulkes A, Thiel B, Pistilli M, Mackiewicz A, Shull J, Montaner LJ. Papasavvas E, et al. Among authors: gross r. PLoS Med. 2004 Dec;1(3):e64. doi: 10.1371/journal.pmed.0010064. Epub 2004 Dec 28. PLoS Med. 2004. PMID: 15630469 Free PMC article. Clinical Trial.
HIV type 1 chemokine coreceptor use among antiretroviral-experienced patients screened for a clinical trial of a CCR5 inhibitor: AIDS Clinical Trial Group A5211.
Wilkin TJ, Su Z, Kuritzkes DR, Hughes M, Flexner C, Gross R, Coakley E, Greaves W, Godfrey C, Skolnik PR, Timpone J, Rodriguez B, Gulick RM. Wilkin TJ, et al. Among authors: gross r. Clin Infect Dis. 2007 Feb 15;44(4):591-5. doi: 10.1086/511035. Epub 2007 Jan 17. Clin Infect Dis. 2007. PMID: 17243065
Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211.
Gulick RM, Su Z, Flexner C, Hughes MD, Skolnik PR, Wilkin TJ, Gross R, Krambrink A, Coakley E, Greaves WL, Zolopa A, Reichman R, Godfrey C, Hirsch M, Kuritzkes DR; AIDS Clinical Trials Group 5211 Team. Gulick RM, et al. Among authors: gross r. J Infect Dis. 2007 Jul 15;196(2):304-12. doi: 10.1086/518797. Epub 2007 Jun 5. J Infect Dis. 2007. PMID: 17570119 Clinical Trial.
3,220 results